CSNK1G2-AS1: A Potential Drug Target and Biomarker for Cancer

Target Name: CSNK1G2-AS1

NCBI ID: G255193

CSNK1G2-AS1

Other Name(s): C19orf34 | CSNK1G2 antisense RNA 1

CSNK1G2-AS1: A Potential Drug Target and Biomarker for Cancer

CSNK1G2-AS1, also known as C19orf34, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for cancer. Its unique structure and subcellular localization in various tissues have piqued the interest of researchers, and recent studies have suggested that CSNK1G2-AS1 may play a crucial role in the development and progression of various diseases, including cancer.

Structure and Localization

CSNK1G2-AS1 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and pancreas. Its unique feature is its nuclear localization, which is not typical for a RNA molecule. CSNK1G2-AS1 is predominantly localized to the nuclear envelope, where it is involved in various cellular processes, including cell signaling, DNA replication, and repair.

Drug Target Potential

CSNK1G2-AS1's nuclear localization and subcellular localization make it an attractive drug target. Its unique structure and localization have been attributed to various mechanisms, including its ability to interact with various nuclear proteins and histone modifications. Therefore, small molecules that can specifically interact with CSNK1G2-AS1 and modulate its localization and activity have great potential as drugs.

One such small molecule, called U0126778, has been shown to inhibit the activity of CSNK1G2-AS1 and reduce its nuclear localization in cancer cells. This compound was found to be a potent inhibitor of CSNK1G2-AS1-mediated nuclear import and export, leading to a reduction in the amount of nuclear-resident CSNK1G2-AS1 and a decrease in its localization to the nuclear envelope.

Biomarker Potential

The potential use of CSNK1G2-AS1 as a biomarker for cancer has also been investigated. cancer cells often have altered levels of various proteins and RNA molecules, including CSNK1G2-AS1. Therefore, measuring the levels of CSNK1G2-AS1 in cancer cells may provide an indirect measure of the disease severity and potential for treatment.

Studies have shown that CSNK1G2-AS1 is overexpressed in various types of cancer, including breast, lung, and colorectal cancer. This overexpression is associated with poor prognosis and poor patient outcomes. Therefore, targeting CSNK1G2-AS1 with small molecules or other therapeutic approaches may be a promising strategy for cancer treatment.

Conclusion

CSNK1G2-AS1 is a unique RNA molecule that has the potential to serve as a drug target and biomarker for cancer. Its nuclear localization and subcellular localization, as well as its involvement in various cellular processes, make it an attractive target for small molecules. Furthermore, its overexpression in various types of cancer and its potential as a biomarker make it a promising candidate for cancer treatment.

While further research is needed to fully understand the role of CSNK1G2-AS1 in cancer, its potential as a drug target and biomarker is undeniable. As research continues to advance, the use of CSNK1G2-AS1 as a therapeutic approach for cancer may become a reality.

Protein Name: CSNK1G2 Antisense RNA 1

The "CSNK1G2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSNK1G2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets